Karnofsky Performance Scale: Clinical Purpose and Application

Primary Purpose

The National Comprehensive Cancer Network recommends using the Karnofsky Performance Scale (KPS) as a prognostic indicator and a critical tool for treatment decision-making in cancer patients, assessing functional status based on activity level, work capacity, and self-care abilities 1, 2, 3

The KPS scale ranges from 0 to 100 in increments of 10, with higher scores indicating better functional status and lower scores (particularly <60) associated with poor survival and serious illness 1, 2, 3
The scale evaluates three core domains: activity level, ability to work, and self-care capacity 1, 2, 3

Patients with KPS <60 should receive best supportive care only, without systemic chemotherapy, as recommended by the National Comprehensive Cancer Network 1, 2, 3
Patients with KPS ≥60 are candidates for systemic therapy with or without best supportive care, or enrollment in clinical trials, according to the National Comprehensive Cancer Network 1, 2, 3
Three-drug chemotherapy regimens should be reserved exclusively for patients with good performance status (KPS ≥80), while two-drug regimens are preferred for those with lower scores, as recommended by the National Comprehensive Cancer Network 1, 2, 3

The KPS is incorporated into the Palliative Prognostic Score (PaP) alongside other clinical factors to predict 30-day survival probability, as suggested by Praxis Medical Insights 4

The KPS is inherently subjective, which can affect inter-rater reliability and introduce potential bias, particularly for borderline scores, as noted in Clinical Cancer Research 5
Clinicians tend to assign higher (worse) KPS scores to patients aged >65 compared to younger patients, despite no objective difference in physical activity, representing age-related bias, as reported in Clinical Cancer Research 5
The KPS is less predictive of cancer-related outcomes in older adults compared to younger populations, as found in Clinical Cancer Research 5
Current KPS scoring does not differentiate the underlying cause of poor performance status (disease burden vs. comorbidities vs. treatment toxicity), which is clinically relevant since patients with disease-related poor performance may improve with effective treatment, as discussed in Clinical Cancer Research 5

The Palliative Performance Scale (PPS) expands beyond KPS by incorporating additional domains including ambulation, self-care, and oral intake, providing more comprehensive assessment in palliative care settings, as described by Praxis Medical Insights 4